The collaboration between ALZpath and Beckman Coulter marks a significant step toward making early detection more accessible and less invasive. The introduction of a blood-based diagnostic test, featuring ALZpath’s novel pTau217 antibody, could transform how Alzheimer’s is diagnosed and treated worldwide. In this Q&A, Chad Holland, president and CEO at ALZpath, and Frederic Jean, vice president strategy and business development at Beckman Coulter, share insights into this groundbreaking partnership and its potential impact.
How do you foresee the landscape of early Alzheimer’s diagnosis changing globally with the integration of ALZpath’s pTau217 antibody into Beckman Coulter’s DxI 9000 Immunoassay Analyzer?
Chad Holland (CH): Alzheimer’s and related dementias are expected to impact nearly 139 million people globally by 2050. Current diagnostics like PET imaging and spinal taps, though effective, are invasive, costly, and inaccessible to many. Blood-based biomarkers, like our pTau217 antibody, offer a scalable and less invasive alternative. This antibody is integral to advanced blood-based tests that are transforming Alzheimer’s diagnosis, treatment, and real-time disease monitoring.
Our collaboration with Beckman Coulter aims to democratize access to the pTau217 antibody, developing it into a highly accurate blood-based test on the DxI 9000 analyzer. This will expand global access to precision diagnostics, significantly enhancing early diagnosis and treatment initiation as new therapies emerge.
Frederic Jean (FJ): One major challenge for the widespread adoption of a new Alzheimer’s blood test will be clinician education. While media interest will likely be high, clinicians need detailed information on the assay’s clinical utility. We’re establishing partnerships with Alzheimer’s research centers, pharmaceutical companies, and patient advocacy groups to generate and share clinical evidence. This will help drive the creation of new guidelines and encourage adoption.
What makes the pTau217 antibody stand out in terms of diagnostic accuracy and sensitivity compared to other biomarkers?
CH: Despite Alzheimer’s prevalence, with 55 million affected globally, nearly 75% of patients remain undiagnosed. Traditional diagnostics are invasive, expensive, and often lead to long wait times. Blood-based tests offer a less invasive and more accessible alternative, but detecting Alzheimer’s biomarkers in the bloodstream requires high precision.
The pTau217 antibody stands out for its diagnostic accuracy and sensitivity, comparable to PET imaging and CSF analysis. By integrating it into widely available testing platforms, we can provide affordable and convenient blood tests for patients worldwide, revolutionizing Alzheimer’s research and patient care.
FJ: The challenge in neurodegenerative diseases lies in identifying clinically relevant biomarkers circulating at very low concentrations in blood. The synergy between ALZpath’s expertise and our high-sensitivity immunoassay technology offers a unique opportunity to accelerate the identification and development of new biomarkers, potentially beyond Alzheimer’s.
Why did ALZpath choose to partner with Beckman Coulter for this licensing agreement?
CH: ALZpath aims to democratize access to our robust pTau217 antibody, enabling its use by researchers, clinicians, and industry partners globally. Incorporating it into highly sensitive assays run on Beckman Coulter’s DxI 9000 analyzers aligns perfectly with our goal of advancing patient care outcomes on a global scale.
What strategies are in place to ensure this diagnostic tool reaches underserved and rural populations globally?
FJ: We are developing a simple, easy-to-use blood test that will be available on Beckman Coulter’s fully automated immunoassay platform, used in hospitals and laboratories across more than 110 countries. Our range of analyzers meets the needs of various laboratory sizes, from small rural hospitals to large central labs, ensuring consistent quality of results worldwide.
Can you share a specific example where this new blood-based test could significantly alter a patient’s diagnostic journey or treatment plan?
CH: The pTau217 antibody enters the market at a critical time for early Alzheimer’s detection, allowing patients to benefit from advanced therapies, specialized care, and early interventions. Traditional diagnostics can take up to nine months, during which patients may experience cognitive decline. Our antibody, once commercialized, will enable rapid, convenient, and affordable blood testing, significantly improving diagnosis and treatment timelines.
The partnership between ALZpath and Beckman Coulter holds the promise of transforming Alzheimer’s diagnosis and care, bringing cutting-edge, accessible diagnostic tools to the global stage. As these innovations reach more patients, the landscape of Alzheimer’s treatment could be fundamentally altered, offering hope for millions affected by the disease.
